Patent ID: 7404962

Claim:
A method for the treatment of malaria caused by P. vivax comprising administration of a first anti-malarial agent, chloroquine phosphate and a second anti-malarial agent having the structural formula [3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]-dihydro-2(3H)-furanone] (compound I) in predetermined doses and a predetermined sequence over a period of six days, said method comprising: a) administering three tablets containing 500 mg each of chloroquine phosphate alone (equivalent to 300 mg chloroquine base) on day one; b) administering one capsule containing 25 mg of compound I concurrently with a tablet containing 500 mg of chloroquine phosphate (equivalent to 300 mg chloroquine base) from day two to three; and c) administering one capsule containing 25 mg of compound I alone from day four to six.